Research carried out by Sandoz into three glycosylated protein biotechnology drugs currently on the market showed quality changes over the period studied. Since all three drugs remained on the market with unchanged labels, this would indicate that the changes were accepted by the health authorities [1].
Acceptable changes in quality for glycosylated biologicals
Biosimilars/Research | Posted 06/05/2011 0 Post your comment
This seems to be good news for biosimilars – which are trying to prove ‘similarity’. Since, if the originators themselves can have such variability then the biosimilars may not have to be as ‘similar’ as originally thought.
What are acceptable quality changes has been in debate since the first marketing approvals of biologicals. This issue is especially relevant when we talk about manufacturing processes, which can be affected by process improvements, scale changes or site transfers, to name just a few.
Health authorities are of the opinion that changes in quality attributes are only acceptable if they do not change the safety and efficacy. But this seems to be based more on a principle than on scientific fact.
The research studied three glycosylated recombinant therapeutic proteins; darbepoetin alfa (Aranesp), rituximab (Rituxan/Mabthera) and etanercept (Enbrel) which were available on the market between 2007 and 2010. The data showed examples of acceptable variations for products that have remained on the market with unchanged product labels.
The following series of three articles discuss the quality changes found in each of the three glycosylated protein biologicals studied.
Related articles
Etanercept and quality attributes changes
Quality attributes changes for rituximab
Changes in the quality attributes of darbepoetin alfa
Reference
1. Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011;29(4):310-2.
News
First denosumab biosimilars approved in Canada and the US
Dr Reddy's launches bevacizumab biosimilar Versavo in the UK
General
Brazil advances in follow-on biologicals/biosimilars approvals, trailing Europe
Insurer perspective on increasing biosimilar uptake in Canada
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Comparing biosimilar adoption: Medicare Advantage versus traditional Medicare
Questioning the need for ethnic sensitivity assessments for biosimilar monoclonal antibodies
ANVISA's role in biosimilar medicine regulation and innovation promotion
Infliximab discontinuation in patients with originator retransition vs biosimilar continuation
Comments (0)
Post your comment